TRANSFORMING PHARMA WITH SYNTHETIC BIOLOGY

Our Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Pipeline

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Product
Proof of concept
R&D
Pilot
API validation
On market
Buprenorphine 50%
Naloxone 50%
Naltrexone 50%
Other Nal products 50%
Prostaglandis 50%

Our focus

Platform Technologies

Integrating Synthetic Biology with Traditional Chemistry

Our Hybrid Platform is Solving Industry Challenges

Traditional methods of producing alkaloid APIs are complex, environmentally challenging and expensive.

River Stone Biotech’s manufacturing and process development capabilities couple fermentation with improved chemistry methodology. This combination approach enables flexible intermediates to be taken into more streamlined chemistry conversion processes, driving efficiencies across many criteria.

The result is a first-in-kind platform that solves key industry challenges – reducing complexity, waste and cost.

A Spotlight on Substance Use Disorders

Priority Market

Our priority focus is on the very expensive APIs buprenorphine, naloxone and naltrexone – used in treatments for opioid use disorder, alcohol use disorder, opioid overdose and pain. In line with high prevalence of these indications, we expect an increasing need for production of these life-changing APIs.

Publications & Presentation

View our select investor presentations and scientific publications for the latest information and updates

Pipeline

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Product
Proof of concept
R&D
Pilot
API validation
On market
Buprenorphine 50%
Naloxone 50%
Naltrexone 50%
Other Nal products 50%
Prostaglandis 50%

Pipeline

Følg med vores nuværende produktion af… 
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Products

Proof of concept

R&D

Pilot

API validation

On market

Any questions?

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Scroll to Top